Overview

Assessment of Abuse Potential of Cebranopadol in Humans

Status:
Recruiting
Trial end date:
2022-10-30
Target enrollment:
Participant gender:
Summary
This study will be conducted to evaluate the abuse potential of single doses of cebranopadol as compared with oxycodone, tramadol and matching placebo in recreational drug users.
Phase:
Phase 1
Details
Lead Sponsor:
Tris Pharma, Inc.
Treatments:
Oxycodone
Tramadol